Research Developments in Rheumatoid Arthritis
| Overview / Abstract: |
The past decade has provided numerous advances in the treatment of rheumatoid arthritis. As will be discussed, recent evidence of 2 medications from different classes provide reassurance as to their long-term safety and efficacy. Of key importance is that these treatment advances provide a real opportunity to achieve disease remission using a treat-to-target approach. The benefits of achieving long-term disease remission vs low disease activity are presented. Join Dr. Roy Fleischmann as he discusses this recent evidence from the American College of Rheumatology Convergence 2020 virtual annual meeting and the implications for clinical practice. |
|
Expiration |
Nov 29, 2021 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physical Therapy CE, Physician CME, Physician Assistant CME |
|
Format |
Webinar / Webcast / Video |
|
Credits / Hours |
.75 AMA PRA Category 1 Credit™ |
|
Accreditation |
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
|
Presenters / Authors / Faculty |
Roy M. Fleischmann, MD |
|
Activity Specialities / Related Topics |
Family Medicine, Primary Care, Rheumatology / Arthritis |
|
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Sanofi Genzyme. |
|
Keywords / Search Terms |
Annenberg Center for Health Sciences at Eisenhower Rheumatoid Arthritis Treatment of RA Disease Remission in RA Baricitinib safety Sarilumab safety and efficacy Free CE CME |
|